Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Inclusion Criteria:

Subjects ≥18 years of age at the time of signing informed consent
Histologically or cytologically documented locally advanced or metastatic NSCLC, SCCHN, CRC, or RCC
Progressed or was intolerant to all available therapies known to confer clinical benefit appropriate for the tumor type
Adequate organ function
At least 1 measurable lesion per RECIST 1.1

Exclusion Criteria:

Treatment with anti-cancer therapy within 28 days or ≤5 elimination half-lives, whichever is earlier, before enrollment
Prior treatment with EGFR-targeted bispecific T cell engager or CAR-T cell therapy
Prior treatment with CD3 engaging bispecific antibodies
Clinically significant cardiovascular diseases
Active clinically significant infection (bacterial, viral, fungal, mycobacteria, or other)
On supplemental oxygen
Any medical condition or clinical laboratory abnormality likely to interfere with assessment of safety or efficacy of study treatment